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 i  
Abstract 
 
Achondroplasia is a form of short-limbed dwarfism caused by a highly conserved, Gly-
Arg mutation in the transmembrane region of fibroblast growth factor receptor 3 
(FGFR3). [Rousseau et al, 1996]  The goal was to infect different cell lines with 
lentivirus carrying shRNA to FGFR3, and quantify the knockdown of FGFR3 mRNA.  
To do this, establishment of a proper cell line was necessary.   Mouse embryonic 
fibroblasts (MEFs) and C3H10T1/2 cells were differentiated for 12 days to determine 
maximal expression of FGFR3.  The MEF cells were then infected with the lentiviral 
vector, and FGFR3 levels were again analyzed.   Knockdown was observed, as expected, 
in the MEFs, with an overall decrease of 90% over uninfected.    It thus appears that the 
shRNA, delivered by lentiviral vector, decreased the amount of FGFR3 being expressed.   
In the future, a more specific sequence against mutant FGFR3 can be engineered, and 
viral infection of this sequence could down regulate the expression of the mutFGFR3, 
while sparing the wild type FGFR3, reestablishing bone growth in achondroplastics. 
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Introduction 
 
Achondroplasia (ACH) is a disease afflicting approximately 1 in 15,000 live births, and accounts 
for more than 90% of all diseases resulting in dwarfism.  [Rousseau et al., 1996, Waller et al., 
2008]   The disease is brought about by a disruption in the process of endochondral ossification 
in the growth plate.   Endochondral ossification is the process by which long bones are formed.   
It begins when mesenchymal cells condense to form chondrocytes. These chondrocytes then 
undergo a process of further maturation and progress to hypertrophic chondrocytes, which are 
characterized by an increase in size, formation of a cartilaginous matrix, and secretion of 
molecules such as vascular endothelial growth factor (VEGF), which allows for the formation of 
blood vessels.   The invasion of blood vessels allows for osteoclasts and osteoblasts to invade 
and remodel the cartilage matrix and form mineralized bone. [Cameron et al., 2009]   The result 
for achondroplastics is that their bones don’t grow properly at their growth plates.   They 
experience rhizomelic dwarfism, where the hip and shoulders are truncated, exaggerated lumbar 
lordosis, stemming from the lack of growth in their vertebrae, and minimal proliferation of the 
growth plate cartilage of long bones.  [Naski et al., 1996, Rousseau et al., 1996, Deng et al., 
1996]   Essentially, wherever the bone is supposed to become longer, achondroplastics 
experience little to no growth.   This results in an extremely short stature as compared to 
individuals without the disease (Figure 1).   Patients suffering from Achondroplasia are still, 
however, able to reproduce, and have normal intelligence, with a mean life span of 61 years, 
compared to a mean general population of 71 years of age.  [Waller et al., 2008]    
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Figure 1:  A picture of achondroplastics taken at the turn of the century.  [Carr, 2005] 
 
This common form of chondrodysplasia is now known to be caused by one of two point 
mutations (G1138A or G1138C) at chromosome locus 4p16.3.   The mutation causes a Gly-Arg 
substitution at position 380, located in the hydrophobic domain of fibroblast growth factor 
receptor 3 (FGFR3).  [Vajo et al., 2000, Rousseau et al., 1994]     
 
FGFR3, like most fibroblast growth factor receptors, consists of 3 extracellular immunoglobulin-
like domains, for binding of the signal peptide, usually acidic and basic fibroblast growth factors, 
a single transmembrane segment, for propagation of the signal through the membrane, and a 
cytoplasmic tyrosine kinase catalytic domain (Figure 2).  [Bruford, 2009]   As with other 
receptor tyrosine kinases, the ligand binding creates a dimerization of two FGFR3 enzymes.   
This allows the two catalytic domains of the cytoplasmic region of the receptors to add 
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phosphates to each other, a process known as 
autophosphoralation.   This serves two main 
purposes.   Firstly, the adding of phosphates to the 
cytoplasmic tails increases the kinase activity of 
the enzyme.   Secondly, and mainly, the 
phosphoralted tyrosines surrounding the catalytic 
sites of the cytoplasmic tails become excellent 
docking stations for intracellular proteins that in 
turn become activated, propagating the signal 
initiated by the binding of the ligand to the 
receptor. [Alberts, Johnson, Lewis, Raff, Roberts, 
and Walter, 2007]  The signal that is propagated 
continues along a path of kinases and transcription 
factors, in an effort to control cell processes 
through the transcription of DNA to produce 
RNA, and the translation of the mRNA into 
proteins (Figure 3). 
                    
Fig. 2:  Schematic representation of fibroblast 
growth factor receptor 3.   The protein consists of 
several immunoglobulin domains (Ig 1-3), a 
transmembrane region (TM), and a cytoplasmic 
catalytic domain made up of two kinase sites.   
The mutation causing Achondroplasia is a G380R 
substitution located in the transmembrane domain 
of the protein. 
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Figure 3:  FGFR Tyrosine Kinase Autophosphoralation  a) Two receptor tyrosine kinases (FGFRs) interacting with 
ligand.  b) Dimerization.  c) Dimerization activates autophosphoralation.  d) Phosphates attract and activate proteins 
in the tyrosine kinase cascade pathway. 
 
a) b) 
c) d) 
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FGFR3 has been found to regulate endochondral ossification through a negative mechanism, 
essentially limiting, rather than promoting, osteogenesis.   In 1996, Deng et al. working at 
Harvard University used murine knockouts of the FGFR3 gene to discover that the knockout 
mice displayed characteristics opposite to the dwarfed phenotype expressed by human 
achondroplastics;  the mice showed prolonged, accelerated bone growth and endochondral 
ossification.   The scientists, therefore, suggested that the mutant variant of FGFR3 apparent in 
Achondorplasia does not create a loss-of-function in the FGFR3, but is a ligand-independent 
activation of the receptor.  [Deng et al., 1996]   As the ACH substitution is located in the 
transmembrane portion of the protein, it is theorized that the tyrosine kinase function is altered 
by the replacement of a hydrophobic guanine with a highly charged arginine.   The receptor 
subsequently dimerizes as a result of the mutation without any fibroblast growth factor binding 
to initiate the dimerization.   [Rousseau et al., 1994]   Therefore, this highly conserved mutation 
(97% of all achondroplastics) creates a dominant negative mutant protein, designated mutFGFR3.  
[Vajo et al., 2000, Naski et al., 1996]   Because of the already negative mechanism of wild type 
FGFR3 (wtFGFR3), the mutant receptor enhances the limiting nature of the receptor, almost 
completely halting endochondral ossification in the long bones, and resulting in an 
achondroplastic’s dwarfed stature.   [Naski et al., 1996, Deng et al., 1996]   One can, therefore, 
gather that if the mutFGFR3 was eliminated from the body, while sparing the wild type receptor, 
the result would show normal bone growth and endochondral ossification. 
 
Stemming from this, our goal begins to become apparent.   A lentivirus could be engineered with 
a small hairpin RNA (shRNA) vector, in order to activate RNA interference in cells expressing 
the mutant receptor.   RNA interference, or RNAi, was first observed in 1986 when Rich 
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Jorgansen of the University of Arizona attempted to insert extra color purple genes into the 
genome of the petunia.  [Fine, 2005]  The resulting flower, however, showed no color 
whatsoever.   After years of hypothesizing and investigating, scientists developed the solution; 
there must have been a mechanism in the cell that viewed the transcribed, extra purple gene 
products as foreign, and concordantly destroyed them.    
 
The theory of RNAi was born.   Pioneered by Craig Mello, using Caenorhabditis elegans and 
Philip Zamore, using Drosophila melanogaster, RNAi has since been catapulted into the 
spotlight.   It was discovered that there are certain enzymes and proteins in the cell, Drosha, 
Dicer, and RISC, which seek to eliminate double stranded RNA (dsRNA) from host cells.   Once 
dsRNA is found, Drosha, an RNAase, creates small hairpin RNAs (shRNAs) from the dsRNA, 
sometimes also referred to as pre-micro inhibiting RNA (pre-miRNA), by cleaving the strands at 
certain positions, and chewing the strands into 21 nucleotide fragments.   Dicer, another 
RNAase, then splits the hairpins into two, complementary strands.   The resulting single stranded 
RNA (ssRNA) fragments are then incorporated into the RNA-induced silencing complex (RISC), 
and used as a template for seeking out, not only foreign RNA complement to the sequences, but 
any RNA in the cell that resembles that sequence.   It is for this reason that the petunias turned 
white; the extra purple mRNA made the cell attack any mRNA signaling the cell to make color 
purple proteins 
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Figure 4:  RNA interference pathway using hairpin miRNA.   Drosha cuts the Pri-miRNA into Pre-miRNA, which is 
exported out of the nucleus.   Then Dicer cleaves the hairpin, creating a miRNA duplex.   When the complement to 
the target strand is incorporated into the RISC complex, translation is halted on the complement mRNA strand. 
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The real amazement, however, is that RNAi can be used as a way to silence gene expression.  
The mechanism is simple: engineer a small hairpin RNA (shRNA) containing a sequence 
complementary to the mRNA being targeted.   Once introduced, the hairpin will be “seen” by the 
host cell as foreign, and will be cleaved, cut, and chewed by Dicer.   The resulting fragments will 
then be incorporated into the RISC complex, and, subsequently, will activate RNAi, destroying 
any mRNA complementary to the chewed sequences.   [Mello et al, 2006] 
 
In 2006, Andrew Fire and Craig Mello won the Nobel Prize in Medicine for discovering this 
fundamental mechanism for controlling gene expression using RNAi.   In Mello’s lecture upon 
receiving the award, he stated that he “encourages [us] all to think about the possibilities, to learn 
more about biology and RNAi, and if [we] get inspired and excited, please join the adventure and 
help explore the many unknowns that are still waiting to be addressed.”  [C. C. Mello, public 
presentation, December 8, 2006]   It is this calling that brings us to the project at hand: treating 
Achondroplasia using RNAi.   Because the mutation (G1138A or G1138C) is so highly 
conserved within the population of achondroplastics, injecting a hairpin RNA sequence 
complementary to the mutant fgfr3 mRNA sequence will activate RNAi against the mutfgfr3 
mRNA, ensuring deletion of mutFGFR3, while sparing wtfgfr3 mRNA.   This, therefore, would 
reestablish the growth plates back to a state of normal growth, because only the wtfgfr3 mRNA 
would be available for translation. 
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Materials and Methods 
 
Mouse Embryonic Fibroblasts were obtained from day E12.5 C57/Bl6 wild type mice.  
C3H10T1/s cells and MEFs were cultured in Dubelcco’s Modified Eagle Media (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS).   For differentiation, cells were plated in 
high-density micromass cultures at a concentration of 107 cells/ml.  Micromass cultures were 
maintained in DMEM/F12 media supplemented with 5% FBS and 50nM BMP2.   Then the cells 
were maintained in culture for 12 days and media was changed on days 2, 5, 8, and 11.    
 
Cells were harvested on days 1,3,6,9, and 12 and total RNA was collected in Trizol.  RNA was 
reverse transcribed into cDNA and FGFR3 mRNA levels were measured in the mouse 
embryonic fibroblasts (MEFs) and C3H10T1/2 (10T1/2) cells using quantitative polymerase 
chains reactions (qPCR), with cyclooxygenase (Cox) as our control mRNA, and SYBR Green I 
as the indicator.   Visual analysis was then performed on the resulting data.    
 
In order to add our shRNA to the MEFs, recombinant viral infections were done, and the 
subsequent knockdown was again measured by qPCR.   The lentivirus containing shRNA 
sequences to FGFR3 had been prepared with a pGIPz (Open Biosystems) backbone, pLP1 
(Invitrogen) packaging plasmid, and pVSV-G (Invitrogen) envelope plasmid.   The cells were 
seeded on 100 mm in normal culture media, and left to grow for 24 hours.   After 24 hours, cells 
were infected with lentivirus.   The media was changed the next day and cells were visualized 
under and Immunoflourescense microscope to determine GFP expression and infection 
efficiency.  Cells were then plated in high-density micromass culture as described above.  Cells 
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were harvested on day 5 and total RNA was isolated in Trizol.  RNA was reverse transcribed into 
cDNA and FGFR3 mRNA levels were determined by qPCR.      
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Results 
 
In order to attempt to treat Achondroplasia in humans, much testing must be conducted in vitro 
and in vivo, in various cell and animal models, and the process must be shown to be successful in 
these models before human testing can be attempted.   The first task, therefore, was to find a 
proper cell line in which to conduct the lentiviral infections of the shRNAs.   We looked into 
various cell lines that we believed were similar to the chondrocytes affected in Achondroplasia.   
C3H10T1/2 cells are mesenchymal progenitors which have the ability to differentiate into a 
variety of different bone precursor cells, such as osteoblasts and chondroblasts.   Derived from 
early mouse embryos, C3H10T1/2 cells have been used extensively as in vitro models to 
examine mesenchymal differentiation into various phenotypic lineages by different inductive 
mediators.  [Shea et al., 2003]   Our primary cell line, however, was the mouse embryonic 
fibroblast line (MEFs).   MEFs had been used for many years to study growth control and DNA 
damage.   However, in 2004, the Department of Cell Biology at the University of Massachusetts 
Medical School demonstrated MEFs in virto can enter, and complete, chondrogenic 
differentiation, or chondrocyte maturation.   They showed that the cells could be induced by 
bone maturation proteins to form 3-dimensional (3-D) cartilaginous tissue.   Their research 
established the MEF as a powerful tool for the study of gene function during chondrogenesis.  
[Lengner et al, 2004] 
 
In order to measure fgfr3 mRNA expression levels accurately, qPCR was conducted on prepared 
MEF and C3H10T1/2 cell aliquots.   To achieve the greatest amount of expression, we 
differentiated the cells for 12 days in BMP-2, in the hopes that the later stages of endochondral 
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ossification would show higher levels of fgfr3 mRNA expression.  After having differentiated 
the cells for 12 days, qPCR was run to show the relative expression levels of the cells at different 
time points (Day 0, Day 1, Day 3, Day 6, Day 9, and Day 12).   The results were then analyzed, 
and are displayed in Table 1 and Figure 5.   The expression levels can be seen to increase as time 
progresses.    In other words, at later differentiation points, there was a greater expression of 
fgfr3 mRNA.   In the C3H10T1/2 cells, the maximal expression level occurred at Day 3, with a 
relative value of 139.74, compared to Day 0 expression levels in that cell line.   However, in the 
MEFs, maximal expression was seen at Day 9, with a much greater value of 1307.87 when 
compared to Day 0 expression levels of the C3H10T1/2.   Therefore, we inferred that the MEF 
cells at Day 9 showed the greatest expression of fgfr3 mRNA. 
 
Sample Detector Relative Diff (+) Diff (-) 
10T1/2 d0 mFGFR3 1.00 0.29 0.22 
10T1/2 d1 mFGFR3 5.05 2.92 1.85 
10T1/2 d3 mFGFR3 139.74 31.11 25.44 
10T1/2 d6 mFGFR3 58.83 26.77 18.40 
10T1/2 d9 mFGFR3 61.91 18.17 14.05 
10T1/2 d12 mFGFR3 41.80 12.60 9.68 
MEF d0 mFGFR3 1.33 0.32 0.25 
MEF d1 mFGFR3 3.41 1.10 0.83 
MEF d3 mFGFR3 12.86 15.09 6.94 
MEF d6 mFGFR3 299.30 109.65 80.25 
MEF d9 mFGFR3 1307.87 726.17 466.92 
MEF d12 mFGFR3 353.63 164.84 112.43 
Table 1: qPCR Analysis.  The table shows relative expression levels of fgfr3 mRNA. 
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Figure 5:  a) Profiling of FGFR3 RNA levels through chondrogenic differentiation of MEFs b) Profiling of FGFR3 
RNA levels through chondrogenic differentiation of C3H10T1/2 c)Relative Expression Levels of MEF (red) to 
C3H10T1/2 cells (blue).   Highest expression level was seen in the MEFs at differentiation stage 5 (day 9). 
 
 
To demonstrate that knockdown could be shown using an RNAi pathway, fgfr3 mRNA levels 
were measured before and after infection of our lentivirus/shRNA vector, using a non-silencing 
(NS) lentivirus as a control.   Although the process showed knockdown from our NS virus, 
further knockdown was observed in cells infected with lentivirus carrying our shRNA vector.   
Therefore, it can be supported that the shRNA vector activated RNAi, and knocked down fgfr3 
mRNA transcription. 
MEF Time Course C3H10T1/2 Time Course 
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Figure 6:   Fgfr3 Knockdown levels in MEFs using relative transcription levels.   Although the non-silencing 
lentivirus (NS/pGIPZ) knocked down mRNA expression in the MEFs, a 3 fold decrease is still observed between the 
NS and the pTRIPZ knockdown in which our vector was transfected. 
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Discussion 
 
The implications brought forth by this study are great in the advancement of a treatment for 
Achondroplasia.   In successfully showing that chondrocyte cells in vitro can be manipulated to 
differentiate and express fgfr3 at maximal levels (Figure 5) gives us a great advantage in 
observing whether fgfr3 is knocked down significantly.   In infecting the cell line, and 
successfully knocking down fgfr3 mRNA expression levels, we are one step closer to treating 
Achondroplasia in humans. 
 
However, one thing that must be overcome is the non-silencing (NS) knockdown that was 
evident in the lentiviral infections of the MEFs (Figure 6).   The process used to plate the MEFs 
for infection, micromass, is highly temperamental.   However, we hypothesize that in infecting 
the cells so early in the growing process, the cells became unstable, and the knockdown observed 
by the NS lentivirus, was a systemic knockdown of all mRNA transcription.   To overcome this, 
we will attempt to let the cells become adapted to the plate and media, and, at a later point, infect 
with the lentivirus.   This will not only serve to show whether we can eliminate such a great NS 
knockdown, but also incorporate the research of the differentiation stages of the cell lines into 
the knockdown equation.   With MEFs, infection at Day 7 would be most probable, as it was at 
Day 9 that maximal expression levels were observed.   Hopefully, the cells will be adapted 
enough to the process that transcription will not be affected by the non-silencing lentivirus, and 
only affected by lentivirus carrying our shRNA vector.   This will then, hopefully, show that our 
shRNA vector activates RNAi in the cell, and show subsequent knockdown of fgfr3 expression. 
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